20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
As a technology, HELIXBALANCE is ready and validated; it only needs clinical trial validation. At the moment, we do not have any gaps to fill, but upgrades and updates will certainly be implemented in the future as a consequence of the R&D activity, producing continuous improvement in the knowledge and in the performance of the technology. The HELIXBALANCE results will need to be integrated with anamnestic data and results from the other tests by means of the development of a proprietary AI. Then, we will need a clinical trial to validate the ability of our AI to integrate information from HELIXBALANCE, the anamnesis, and the other HELIXAFE tests to profile individuals based on their risk of developing colorectal cancer. We also aim at combining HELIXBALANCE with the analysis of mitochondrial dysfunction, to further increase the genomic instability analysis’ predictive value.
